91
Amid NIH funding delays, clawbacks and uncertainty, a scientist at Harvard who studies breast cancer has lost one third of her lab employees and wonders if she can continue her research experiments.
Amid NIH funding delays, clawbacks and uncertainty, a scientist at Harvard who studies breast cancer has lost one third of her lab employees and wonders if she can continue her research experiments.
@2025 – All Right Reserved. Designed and Developed by Kaniz Fatema